| First Author | Plank JL | Year | 2011 |
| Journal | Endocrinology | Volume | 152 |
| Issue | 12 | Pages | 4589-600 |
| PubMed ID | 21952247 | Mgi Jnum | J:179100 |
| Mgi Id | MGI:5301065 | Doi | 10.1210/en.2010-1462 |
| Citation | Plank JL, et al. (2011) Loss of Foxd3 results in decreased beta-cell proliferation and glucose intolerance during pregnancy. Endocrinology 152(12):4589-600 |
| abstractText | A complete molecular understanding of beta-cell mass expansion will be useful for the improvement of therapies to treat diabetic patients. During normal periods of metabolic challenges, such as pregnancy, beta-cells proliferate, or self-renew, to meet the new physiological demands. The transcription factor Forkhead box D3 (Foxd3) is required for maintenance and self-renewal of several diverse progenitor cell lineages, and Foxd3 is expressed in the pancreatic primordium beginning at 10.5 d postcoitum, becoming localized predominantly to beta-cells after birth. Here, we show that mice carrying a pancreas-specific deletion of Foxd3 have impaired glucose tolerance, decreased beta-cell mass, decreased beta-cell proliferation, and decreased beta-cell size during pregnancy. In addition, several genes known to regulate proliferation, Foxm1, Skp2, Ezh2, Akt2, and Cdkn1a, are misregulated in islets isolated from these Foxd3 mutant mice. Together, these data place Foxd3 upstream of several pathways critical for beta-cell mass expansion in vivo. |
